A phase II study of tasisulam sodium as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma

Investigational New Drugs, 05/04/2012

Tasisulam at a target Cmax of 420µg/mL on day 1 of 21–day cycles demonstrated modest activity as second–/third–line treatment in patients with soft tissue sarcoma (STS). Grade 4 hematologic toxicity posed some challenges in these heavily pre–treated patients. Tasisulam dosing continues to be refined.

Print Article Summary Cat 2 CME Report